Mitiglinide (calcium) (Standard)
Mitiglinide (calcium) (Standard) is the analytical standard of Mitiglinide (calcium) . This product is intended for research and analytical applications. Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide Calcium can be used for the research of type 2 diabetes[1][2].
Product Specifications
CAS Number
145525-41-3
UNSPSC
12352100
Target
Potassium Channel; Reference Standards
Related Pathways
Membrane Transporter/Ion Channel; Others
Field of Research
Metabolic Disease
Smiles
O=C([O-])[C@H](CC(N1C[C@](CCCC2)([H])[C@]2([H])C1)=O)CC3=CC=CC=C3.[0.5Ca2+]
Molecular Formula
C19H24NO3.1/2Ca
Molecular Weight
334.44
References & Citations
[1]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740226-100 1x 100 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040352-500 1x 500 µL
CD31 / PECAM-1 (158-2B3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC801037-500 1x 500 µL
CD44 Standard (DF1485), CF680 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 